![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/2/2d/Mab-ozogamicin.svg/640px-Mab-ozogamicin.svg.png&w=640&q=50)
Inotuzumab ozogamicin
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Inotuzumab ozogamicin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.[3][5] It is administered by intravenous infusion.[3][5]
Quick Facts Monoclonal antibody, Type ...
![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD22 |
Clinical data | |
Trade names | Besponsa |
Other names | CMC-544 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617041 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 97% (cytotoxic agent) |
Elimination half-life | 12.3 days |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6518H10002N1738O2036S42 |
Molar mass | 146634.36 g·mol−1 |
![]() ![]() |
Close
The medication consists of a humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.[6]
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]